Shyam Patel to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Shyam Patel has written about Leukemia, Myeloid, Acute.
Connection Strength
10.201
-
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, Bindal P, Ramanathan M, Gerber JM, Cerny J, Patel SA. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025 Apr 15; 131(8):e35846.
Score: 0.821
-
Patel SA. Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia. Leukemia. 2024 Dec; 38(12):2544-2551.
Score: 0.791
-
Patel SA. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia. Br J Haematol. 2024 Apr; 204(4):1137-1138.
Score: 0.756
-
Bello E, Liao H, Patel SA. Clinico-Radio-Pathologic Correlation of Leukostasis in Acute Myeloid Leukemia with FLT3 Mutation. Acta Haematol. 2024; 147(3):388-390.
Score: 0.738
-
Patel SA, Bello E, Wilks A, Gerber JM, Sadagopan N, Cerny J. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations. Leuk Res. 2023 11; 134:107388.
Score: 0.735
-
Patel SA. Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7?+?3. Leuk Lymphoma. 2023 09; 64(9):1503-1513.
Score: 0.723
-
Patel SA, Cerny J. TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology. Blood Adv. 2022 03 22; 6(6):1917-1918.
Score: 0.664
-
Patel SA. Functional genomic approaches in acute myeloid leukemia: Insights into disease models and the therapeutic potential of reprogramming. Cancer Lett. 2022 05 01; 533:215579.
Score: 0.658
-
Patel SA, Lloyd MR, Cerny J, Shi Q, Simin K, Ediriwickrema A, Hutchinson L, Miron PM, Higgins AW, Ramanathan M, Gerber JM. Clinico-genomic profiling and clonal dynamic modeling of TP53-aberrant myelodysplastic syndrome and acute myeloid leukemia. Leuk Lymphoma. 2021 12; 62(14):3348-3360.
Score: 0.640
-
Patel SA, Dalela D, Fan AC, Lloyd MR, Zhang TY. Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy. Leuk Lymphoma. 2022 01; 63(1):10-18.
Score: 0.637
-
Patel SA, Litzow MR, Cerny J. Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia. Blood Rev. 2021 11; 50:100863.
Score: 0.630
-
Patel SA, Bledsoe JR, Gordon J, Cerny J. Extramedullary Acute Myeloid Leukemia of the Renal Pelvis: Insights into a Visceral Niche. Acta Haematol. 2021; 144(3):297-301.
Score: 0.595
-
Patel SA, Gerber JM. A User's Guide to Novel Therapies for Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):277-288.
Score: 0.572
-
Patel SA. Myelodysplastic Syndrome and Acute Myeloid Leukemia Risk Associated With Solid Tumor Chemotherapy. JAMA Oncol. 2019 03 01; 5(3):303-304.
Score: 0.537
-
Patel SA. Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia. JAMA Oncol. 2018 08 01; 4(8):1110-1111.
Score: 0.516
-
Kennedy A, Patel S, Ramanathan M, Gerber J, Cerny J. Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center. Ann Hematol. 2024 Mar; 103(3):1031-1033.
Score: 0.188